New siRNA drug ADX-626 tested in humans for first time

NCT ID NCT07081503

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage study is testing a new drug called ADX-626 in 44 healthy adults to see if it is safe and how the body processes it. Participants will receive either the drug or a placebo (saline). The study does not aim to treat any disease, but to gather important safety information for future research.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

ADX-626 (siRNA drug)

What this could lead to

If successful, this early study could pave the way for future trials of ADX-626 in specific diseases.

What could go wrong

This is a very early Phase 1 study in healthy people, so it won't show if the drug treats any disease. Side effects are possible, and the drug may not work as hoped in later trials.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEALTHY ADULT PARTICIPANTS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Richmond Pharmacology

    RECRUITING

    London, SE1 1YR, United Kingdom

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact